Dave Knapp brings you your weekly dose of everything in the news about incretin mimetic, diabetes and obesity therapies, like Zepbound and Mounjaro, Ozempic and Wegovy, and even investigational treatments like CagriSema and Retatrutide!
All content for On The Pen With Dave Knapp is the property of Bleav, Dave Knapp Founder of On The Pen and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Dave Knapp brings you your weekly dose of everything in the news about incretin mimetic, diabetes and obesity therapies, like Zepbound and Mounjaro, Ozempic and Wegovy, and even investigational treatments like CagriSema and Retatrutide!
FDA CRACKDOWN on Compounded GLP-1s | Novo’s Gut Hack & Lilly’s One-Shot Cure
On The Pen With Dave Knapp
39 minutes 2 seconds
1 month ago
FDA CRACKDOWN on Compounded GLP-1s | Novo’s Gut Hack & Lilly’s One-Shot Cure
🚨 FDA cracks down on compounded GLP-1 medications, raising questions about the future safety, quality, supply, and cost. In this episode of On The Pen Live, we break down what the FDA’s new “green list” means for patients relying on compounded semaglutide and tirzepatide, including risks like dosing errors, unapproved salt forms, and hospitalizations.
We also cover two massive research moves shaking up the future of obesity and diabetes care:
✅ Novo Nordisk + Novonesis team up on gut microbiome therapies, using probiotics and prebiotics (synbiotics) to prevent obesity and improve blood sugar and cholesterol.
✅ Eli Lilly + Remedium Bio launch a gene therapy partnership that could replace weekly GLP-1 injections with a single, long-acting shot.
PLUS: An exclusive interview with Alicia, cofounder of Claimable, about the class action lawsuit against CVS Caremark for forcing patients to switch from Zepbound to Wegovy. We talk timelines, how to get involved, and what it means for patient choice in obesity treatment.
On The Pen With Dave Knapp
Dave Knapp brings you your weekly dose of everything in the news about incretin mimetic, diabetes and obesity therapies, like Zepbound and Mounjaro, Ozempic and Wegovy, and even investigational treatments like CagriSema and Retatrutide!
